CU Anschutz Researchers Develop Nonhormonal Therapy Targeting Root Cause of Genitourinary Syndrome of Menopause
核心洞察
Researchers at CU Anschutz have developed a novel nonsteroidal molecule, 3-fluoro 6,4'-dihydroxyflavone (搜索) (3F), that restores estrogen signaling exclusively in vaginal tissue without systemic exposure.
In a preclinical animal study, the vaginal suppository therapy regenerated the vaginal epithelium lost through estrogen deficiency, addressing the underlying cause of GSM rather than merely managing symptoms.
An estimated 50% to 70% of women experiencing natural or medically induced menopause develop one or more GSM symptoms, yet many avoid hormonal therapies due to concerns about breast cancer and hormone-sensitive cancer risks.
Researchers at the University of Colorado Anschutz (搜索) Medical Campus have developed a novel nonhormonal therapy that may fundamentally change how Genitourinary Syndrome of Menopause (搜索) (GSM) is treated, according to findings published today in the journal Menopause. The preclinical study demonstrates that a newly synthesized molecule can restore estrogen signaling selectively within vaginal tissue, potentially addressing the underlying cause of the condition without exposing the rest of the body to estrogen.
GSM is a common chronic condition triggered by declining estrogen levels that affects the vulva, vagina, and urinary tract. Women with GSM experience vaginal dryness, painful intercourse, and recurrent vaginal and urinary tract infections. An estimated 50% to 70% of women undergoing natural or medically induced menopause develop one or more symptoms of the syndrome.
"For too many women, the current options are either products that only provide temporary relief or hormone-based treatments they may not feel comfortable using," said Steve Nordeen, PhD, professor emeritus in the department of pathology at the CU Anschutz School of Medicine and the paper's senior author.
A Tissue-Selective Mechanism of Action
The investigational therapy centers on a novel nonsteroidal estrogen-signaling molecule called 3-fluoro 6,4'-dihydroxyflavone (搜索) (3F). Unlike conventional estrogen replacement therapies that distribute hormones systemically, 3F is designed to activate estrogen signaling pathways only within vaginal tissue. Delivered as a vaginal suppository, the compound successfully regenerated the vaginal epithelium—the cellular lining of the vagina—in a preclinical animal model of menopause, with no evidence of systemic estrogenic activity.
This tissue-selective approach directly addresses a critical unmet need. Many women either cannot or choose not to use hormone therapy because of concerns about potential risks, particularly those with a history of breast cancer or an elevated risk of hormone-sensitive cancers. Current over-the-counter products, meanwhile, offer only limited, temporary symptom relief without tackling the biological mechanisms driving tissue deterioration.
"Our goal was to develop a therapy that addresses the underlying cause of the vaginal changes that follow menopause, not just the symptoms, without relying on steroid hormones," Nordeen said. "While more research is needed, these findings suggest we may have a promising new approach."
Path Toward Clinical Translation
The researchers emphasize that the findings, while encouraging, represent an early step. The next phase involves securing the necessary support to advance 3F into human clinical trials, where its safety and efficacy can be rigorously evaluated in women with GSM.
"Our findings suggest the prospect of a safer and more effective therapy is within reach," Nordeen said. "The next step is securing the support needed to move this therapy into human clinical trials so we can determine whether it offers women a new treatment option."
If future clinical trials confirm the preclinical results, the therapy could provide a new option for millions of women who currently face a difficult choice between enduring painful symptoms, relying on products with limited efficacy, or accepting the potential risks associated with systemic hormone therapy.